Butterfly Network's silicon-based ultrasound could turn specialist imaging into a home device that improves as scans and outcomes train its AI. That iPhone-like shift depends on crossing the harmonics gate; Apple reached $5T thanks to the iPhone, while Butterfly trades at $2B and could similarly change how we see inside our bodies. x.com  x.com 

Hyperfine offers good risk/reward as its first FDA-cleared AI-powered portable MRI moves from R&D to commercialization. It sold 10 units in Q1 2026, is winning approvals in markets such as the UK and India, and works with Nvidia and the Gates Foundation. Gross margin rose to 50.7% from 41.3%, cash burn fell 13%, and $40.8M of cash gives runway into 2028, easing dilution. Insiders own about 31% with hardly any sales, and it is set to join the Russell 2000 after June 26. x.com  x.com 

AI-enabled healthcare and genomics could deliver the next photonics-like returns, as AI transforms the sector and improves success rates just as it did in tech. The market is getting ready to price these names as future winners, and those that succeed will be real winners. Beaten-down stocks such as AbCellera, Tempus AI and Twist Bioscience, plus the ARK Genomic Revolution ETF, are looking at billion-dollar markets. x.com 

Biotech is the next AI trade, as AI turns drug discovery from a 10-year guessing game into a data problem while investors still treat the sector like a casino. Tempus AI uses a large clinical dataset for AI diagnostics; Recursion maps over a trillion cells with Genentech and Sanofi as partners; CRISPR Therapeutics has catalysts before end-2026; Absci designs antibodies with generative AI and starts Phase 2; Schrödinger sells physics-plus-AI design software and posted a surprise profit. x.com  … Show more

AI biotech names such as Tempus AI, Recursion, Ginkgo Bioworks and Prime Medicine could become the new home for money rotating out of AI and semiconductor leaders, with Moderna and Merck's positive phase 3 melanoma results for their mRNA neoantigen therapy a possible catalyst. Sentiment toward AI in healthcare should be far warmer than toward job-displacing AI, since everyone faces disease, and could top the semis trade. Indices could chop or fall while these biotechs outperform. x.com  x.com  … Show more

GE HealthCare's chart looks constructive and September call options carry low implied volatility. Medical device and diagnostics companies may also see a rotation driven by physical AI. x.com  x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

Rotation out of extended semis, AI and tech infrastructure is structural oxygen for a broader bull market, not a bearish signal, as capital flows into software, healthcare, financials and payments. Favored names include Snowflake, Shopify, Datadog and Samsara in enterprise tech; Visa, Robinhood, Affirm, SoFi, Mastercard and American Express in finance; and UnitedHealth, Eli Lilly, Oscar Health, Hims & Hers and Moderna in healthcare. x.com 

AI now makes early disease detection possible at scale, and catching disease early is always cheaper than treating it late. Detection names like Grail, Guardant, RadNet and Lunit win on distribution and reimbursement; grading names like Tempus, Veracyte, GE HealthCare and HeartFlow build data moats near treatment decisions. Monitoring via Natera, Personalis and iRhythm is the most asymmetric layer, a recurring subscription. NVIDIA gets paid whichever test wins. x.com 

Therapeutics and genomics are a hot theme that retail traders, focused on AI and software, have not yet noticed. Healthcare, drugs and biotech have been strong for the last few months. Favorites in the group are Revolution Medicines, Twist Bioscience, Halozyme and TG Therapeutics. x.com